在现实世界中研究药物安全性。 - Suppr

Suppr

超能文献

Studying Drug Safety in the Real World.

作者信息

Zipursky Jonathan, Juurlink David N

机构信息

Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

出版信息

JAMA Intern Med. 2018 Nov 1;178(11):1533-1534. doi: 10.1001/jamainternmed.2018.5766.

DOI:10.1001/jamainternmed.2018.5766

PMID:30304435

Abstract

摘要

相似文献

Studying Drug Safety in the Real World.

JAMA Intern Med. 2018 Nov 1;178(11):1533-1534. doi: 10.1001/jamainternmed.2018.5766.

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.

Arthritis Care Res (Hoboken). 2015 Feb;67(2):280-7. doi: 10.1002/acr.22409.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

Safety and efficacy of allopurinol in chronic kidney disease.

Ann Pharmacother. 2013 Nov;47(11):1507-16. doi: 10.1177/1060028013504740. Epub 2013 Oct 9.

Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.

Am J Med. 2006 Nov;119(11 Suppl 1):S29-31. doi: 10.1016/j.amjmed.2006.06.027.

The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.

Clin Ther. 2016 Jul;38(7):1710-25. doi: 10.1016/j.clinthera.2016.05.007. Epub 2016 Jun 3.

Treatment of gout patients with impairment of renal function: a systematic literature review.

J Rheumatol Suppl. 2014 Sep;92:48-54. doi: 10.3899/jrheum.140462.

Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.

Arthritis Rheumatol. 2016 Oct;68(10):2563-4. doi: 10.1002/art.39769.

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Ann Rheum Dis. 2017 May;76(5):811-820. doi: 10.1136/annrheumdis-2016-209213. Epub 2016 Nov 7.

Urate-lowering therapy for gout: focus on febuxostat.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594.

引用本文的文献

Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use.

Drug Saf. 2020 Jun;43(6):567-582. doi: 10.1007/s40264-020-00915-6.

Pharmaco-epidemiological research on herbal medicinal products in the paediatric population: data from the PhytoVIS study.

Eur J Pediatr. 2020 Mar;179(3):507-512. doi: 10.1007/s00431-019-03532-3. Epub 2019 Dec 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Studying Drug Safety in the Real World.

作者信息

Zipursky Jonathan, Juurlink David N

机构信息

Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

出版信息

JAMA Intern Med. 2018 Nov 1;178(11):1533-1534. doi: 10.1001/jamainternmed.2018.5766.

DOI:10.1001/jamainternmed.2018.5766

PMID:30304435

Abstract

摘要

相似文献

Studying Drug Safety in the Real World.

JAMA Intern Med. 2018 Nov 1;178(11):1533-1534. doi: 10.1001/jamainternmed.2018.5766.

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.

Arthritis Care Res (Hoboken). 2015 Feb;67(2):280-7. doi: 10.1002/acr.22409.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

Safety and efficacy of allopurinol in chronic kidney disease.

Ann Pharmacother. 2013 Nov;47(11):1507-16. doi: 10.1177/1060028013504740. Epub 2013 Oct 9.

Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.

Am J Med. 2006 Nov;119(11 Suppl 1):S29-31. doi: 10.1016/j.amjmed.2006.06.027.

The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.

Clin Ther. 2016 Jul;38(7):1710-25. doi: 10.1016/j.clinthera.2016.05.007. Epub 2016 Jun 3.

Treatment of gout patients with impairment of renal function: a systematic literature review.

J Rheumatol Suppl. 2014 Sep;92:48-54. doi: 10.3899/jrheum.140462.

Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.

Arthritis Rheumatol. 2016 Oct;68(10):2563-4. doi: 10.1002/art.39769.

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Ann Rheum Dis. 2017 May;76(5):811-820. doi: 10.1136/annrheumdis-2016-209213. Epub 2016 Nov 7.

Urate-lowering therapy for gout: focus on febuxostat.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594.

引用本文的文献

Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use.

Drug Saf. 2020 Jun;43(6):567-582. doi: 10.1007/s40264-020-00915-6.

Pharmaco-epidemiological research on herbal medicinal products in the paediatric population: data from the PhytoVIS study.

Eur J Pediatr. 2020 Mar;179(3):507-512. doi: 10.1007/s00431-019-03532-3. Epub 2019 Dec 11.